Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of injectable paromomycin versus amphotericin B for visceral leishmaniasis in India
ISRCTN68386084Phase 3Completed
- Sponsor
- UNICEF
- Start
- May 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in visceral leishmaniasis (VL) comparing Paromomycin with Amphotericin B control (2 arms). Primary endpoints: Reported adverse events, Protocol-defined nephrotoxicity and ototoxicity and 2 more. Started May 2003; status: completed.
02
Drugs
paromomycinamphotericin b
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on ISRCTN68386084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68386084.